Testicular Cancer Research Explained

A 95% cure rate is good—but not good enough

Five decades ago, a man diagnosed with testicular cancer had a survival rate of just 5 percent. Today, that number is 95 percent.

The tables turned on testicular cancer thanks to a chemotherapy regimen developed by Larry Einhorn, MD. Today, hundreds of thousands of men around the world are alive because of this treatment protocol.

For these survivors, IU research has led to the gift of a long life. But the IU team still isn’t satisfied. They continue to chip away at the survival rate, finding ways to save men who do not respond to initial therapies. For example, our researchers are collaborating with bioengineers on a compound to signal the immune system to attack testis cancer cells.

IU researchers are also focused on reducing the “cost of the cure”—the long-term side effects that sometimes come with treatment. We lead a global team of researchers looking to reduce the toll of treatment, including tinnitus, hearing loss, cardiovascular issues, and numbness in extremities.

IU remains the international leader in testis cancer research and care, drawing patients from Indiana and around the world.

#ResearchCuresCancer.

Don’t miss: Dr. Einhorn answers questions about testicular cancer

Cancer survivor, cancer scientist: Eamon’s story

Eamon Eccles was a 19-year-old sophomore at IU-Bloomington when testicular cancer upended his college life. After a successful surgery, his oncologist introduced him to Dr. Einhorn as part of a five-year surveillance plan to make sure his cancer didn’t return.

That experience inspired Eamon to switch from biology to oncology. After graduating from IU School of Medicine in May 2022, Dr. Eccles is now an IU resident in internal medicine and pediatrics.

His advice for cancer patients of any age? “Let’s do what we’ve got to do.”

Read Eamon’s Story

Expert advice: A survivor interviews his surgeon

Newscast director Steven Crocker isn’t shy about using humor when he’s advocating for fellow testicular patients and survivors. His Twitter bio proudly proclaims “Abundance of ball and nut jokes because I’m a @testescancer survivor.”

Steven joined oncologist Dr. Clint Cary for our Simon Says Expert Series titled—unsurprisingly—”Keeping Our Eyes on the Ball.”

During the interview, Dr. Cary explained the latest treatment options, including innovative nerve-sparing surgical techniques developed at IU.

Be sure to check out the Testicular Cancer Awareness Foundation’s new podcast. It’s titled—unsurprisingly—It Takes Balls.

A legacy of discovery

In the early 1970s, John Cleland’s testicular cancer wasn’t responding to treatment. When he was offered  a highly experimental new chemotherapy regimen, he trusted his oncologist enough to accept.

It worked. For the next 47 years, John taught biology, coached athletes, ran marathons, carried an Olympic torch, judged dairy contests, and loved life in Zionsville with his family.

To honor John’s legacy, his oncologist Lawrence Einhorn, MD, and IU Simon Comprehensive Cancer Center established the John Cleland Fellowship Fund to encourage ongoing testis cancer research conducted by IU oncology trainees.

Your gift will help us ensure that this trailblazing hero continues to inspire more generations of hope.

• Donate online today through the IU Foundation
• Read John’s obituary in the Indianapolis Star
• Listen to the Journal of Clinical Oncology’s “Cancer Stories” podcast

The Platinum Study: Finding a better “new normal”

Cisplatin therapy is sometimes referred to as a “marvel.” The American Society of Clinical Oncologists rates it among its top five cancer research breakthroughs.

It’s also the cause of numerous, and sometimes debilitating, side effects. Scientists like Lois Travis, MD, call chemotherapy-related conditions like hearing loss and nerve damage “toxicities.”

Dr. Travis and her mentor Dr. Einhorn hate that word. Their current research, known as The Platinum Study, aims to make it obsolete.

Nearly 2,000 testicular cancer survivors are participating in the study, sharing their health histories and volunteering for in-person testing. By analyzing all that data, Dr. Travis and her colleagues around the world are pinpointing the causes of cisplatin toxicity–and learning how to prevent it.

Platinum Study Meet Dr. Travis